hydromorphone; dihydromorphinone (Dilaudid, Palladone)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradenames: Dilaudid, Palladone[5]. DEA-controlled substance: class 2.

Indications

Dosage

Tabs: 1, 2, 3, 4 mg.

* Palladone (extended-release)[4]

Suppositories: 3 mg.

* Oral doses 20% to 50% as potent as parenteral administration. marketing & sales suspended due to alcohol interactions[7]

Pharmacokinetics

elimination via liver

1/2life = 1.5-4 hours

protein binding = 14 %

Adverse effects

Drug interactions

Laboratory

Mechanism of action

opiate

More general terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  3. Clinical Guide to Laboratory Tests, 3rd ed. Teitz ed., W.B. Saunders, 1995
  4. 4.0 4.1 Prescriber's Letter 12(3): 2005 Palladone (Hydromorphone Extended-release Capsules) Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210308&pb=PRL (subscription needed) http://www.prescribersletter.com
  5. 5.0 5.1 5.2 FDA Medwatch http://www.fda.gov/medwatch/SAFETY/2005/safety05.htm#Palladone
  6. Department of Veterans Affairs, VA National Formulary
  7. 7.0 7.1 Prescriber's Letter 13(2): 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220215&pb=PRL (subscription needed) http://www.prescribersletter.com
  8. Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001
  9. Chang AK et al, Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: A randomized clinical trial. Ann Emerg Med 2006, 48:164 PMID: https://www.ncbi.nlm.nih.gov/pubmed/16857467
  10. 10.0 10.1 Solomon DH et al. The comparative safety of opioids for nonmalignant pain in older adults. Arch Intern Med 2010 Dec 13/27; 170:1979. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21149754
    Becker WC, O'Connor PG. The safety of opioid analgesics in the elderly: New data raise new concerns: Comment on "The Comparative Safety of Opioids for Nonmalignant Pain in Older Adults". Arch Intern Med 2010; 170(22):1986-1988. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21149755
    Papaleontiou M, Henderson CR, Turner BJ, et al. Outcomes associated with opioid use in the treatment of chronic noncancer pain in older adults: a systematic review and meta-analysis. J Am Geriatr Soc 2010; 58(7):1353-1369. Epub 2010 Jun 1. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20533971
  11. 11.0 11.1 Chang AK et al. Randomized clinical trial of efficacy and safety of a single 2-mg intravenous dose of hydromorphone versus usual care in the management of acute pain. Acad Emerg Med 2013 Feb; 20:185 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23406078
  12. Pfizer and Acura Announce FDA Approval of Oxectatm (Oxycodone HCL, USP) CII http://www.pfizer.com/news/press_releases/pfizer_press_releases.jsp#guid=20110620005857en&source=RSS_2011&page=1
  13. 13.0 13.1 Medical Knowledge Self Assessment Program (MKSAP) 17, 19 American College of Physicians, Philadelphia 2015, 2021

Database